Elisabeth Gurnhofer's research while affiliated with Medical University of Vienna and other places

Publications (24)

Article
Full-text available
Purpose: Folate receptor alpha (FRα) is overexpressed in various cancer entities while expression in normal tissue is limited. Thus, FRα is an attractive target in cancer therapy. Currently, various therapeutic and diagnostic approaches are under investigation in clinical trials. The aim of this study was to assess the expression and clinical rele...
Article
Full-text available
Wnt/Beta-Catenin signaling is involved in the carcinogenesis of different solid malignant tumors. The interaction of Creb-binding protein (CBP) with Beta-Catenin is a pivotal component of the Wnt/Beta-Catenin signaling pathway. The first aim of this study was to evaluate the association of CBP expression with survival in patients with human papillo...
Article
Full-text available
The proteins sodium iodide symporter (NIS), μ-crystallin (CRYM), and thyroid hormone receptor beta (THRB) have been associated with prognosis in various cancer entities. While NIS and THRB may serve as possible therapeutic targets, the role of CRYM in cancer is still unclear. Protein levels of 44 patients with adenoid cystic carcinoma of the head a...
Article
Full-text available
Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is still unsatisfactory, and already in second line effective treatment options are lacking. To ide...
Article
Full-text available
Purpose The transcription factors YY1 and CP2 have been associated with tumor promotion and suppression in various cancers. Recently, simultaneous expression of both markers was correlated with negative prognosis in cancer. The aim of this study was to explore the expression of YY1 and CP2 in head and neck squamous cell carcinoma (HNSCC) patients a...
Article
Full-text available
Ewing sarcoma (EwS) is a highly metastatic bone cancer characterized by the ETS fusion oncoprotein EWS-FLI1. EwS cells are phenotypically highly plastic and switch between functionally distinct cell states dependent on EWS-FLI1 fluctuations. Whereas EWS-FLI1 high cells proliferate, EWS-FLI1 low cells are migratory and invasive. Recently, we reporte...
Article
Full-text available
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Article
Full-text available
Prostate cancer (PCa) has a broad spectrum of clinical behavior; hence, biomarkers are urgently needed for risk stratification. Here, we aim to find potential biomarkers for risk stratification, by utilizing a gene co-expression network of transcriptomics data in addition to laser-microdissected proteomics from human and murine prostate FFPE sample...
Article
Full-text available
Objectives: Inhibitors of apoptosis proteins are crucial to carcinogenesis since their expression results in evasion of apoptosis. Overexpression of inhibitors of apoptosis has repeatedly been associated with resistance to treatment and poor prognosis in various cancers. The role of inhibitors of apoptosis in adenoid cystic carcinoma of the saliva...
Article
Full-text available
Overexpression of LAPTM4B-35 (lysosomal-associated transmembrane protein 4β-35) is associated with a poor prognosis in numerous malignant tumours. Expression patterns and effects of LAPTM4B-35 on head and neck squamous cell carcinomas (HNSCC) are unknown. The aim of this study was to investigate the prognostic relevance of LAPTM4B-35 in HNSCC. Tiss...
Article
Background: Lymph node metastases are frequently detected in head and neck squamous cell carcinoma (HNSCC) patients. Little is known about biomarkers expressed in lymph node metastases or their influence on clinical outcome. Doublecortin-like kinase 1 (DCLK1) is one marker that might be associated with outcome, owing to its correlation with stem c...
Preprint
Full-text available
Prostate cancer (PCa) has a broad spectrum of clinical behaviour, hence biomarkers are urgently needed for risk stratification. We previously described the protective effect of STAT3 in a prostate cancer mouse model. By utilizing a gene co-expression network in addition to laser microdissected proteomics from human and murine prostate FFPE samples,...
Article
Full-text available
Salivary gland malignancies of the head and neck form a heterogeneous group. Adenoid cystic carcinomas are an aggressive entity of salivary gland malignancies characterized by frequent distant metastases and poor response to radio- and chemotherapy. AF1Q is a MLL fusion partner, which can activate Wnt and STAT3 signaling. Recently, overexpression o...
Article
Full-text available
TYK2 is a member of the JAK family of tyrosine kinases that is involved in chromosomal translocation-induced fusion proteins found in anaplastic large cell lymphomas (ALCL) that lack rearrangements activating the anaplastic lymphoma kinase (ALK). Here we demonstrate that TYK2 is highly expressed in all cases of human ALCL, and that in a mouse model...
Article
Purpose: Previously, the engulfment and cell motility 3 (ELMO3) protein has been reported to be involved in cell migration and cytoskeletal remodeling. As of yet, nothing is known about the role of ELMO3 in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to asses ELMO3 expression in postoperatively irradiated HNSCC pat...
Article
Full-text available
Proper development of the immune system is an intricate process dependent on many factors, including an intact DNA damage response. The DNA double-strand break signaling kinase ATM and its cofactor NBS1 are required during T cell development and for the maintenance of genomic stability. The role of a second ATM cofactor, ATMIN (also known as ASCIZ)...

Citations

... Based on the expressions of 17 immune genes, we constructed an IGRPM to assess the prognosis of patients with [39], NR3C2 [32,33], SAA1 [40], CXCL5 (C-X-C Motif Chemokine Ligand 5) [41], TLR3(toll-like receptor 3) [42], CLDN4 [43,44], THRB [45], and LGR4 [46]. However, the specific molecular mechanisms of these genes affecting the prognosis of tumor patients are not clear, so the molecular mechanisms of the effect of these genes on KIRC patients need to be further studied in the future. ...
... Recent genomic analyses have led to recognition of several genetic contexts with prognostic implications, although there are currently insufficient data to determine if these are best regarded as prognostic markers or molecular subtypes. ALKnegative ALCL bearing TP63 rearrangements [244], loss of TP53 [244][245][246] and/or overexpression of IL-2Rα [247] are associated with poor outcomes. Although initial reports suggested DUSP22 rearrangement to be associated with a favorable 5-year overall survival comparable to ALK+ ALCL [248], more recent studies have not confirmed this association [249]. ...
... Next, we confirmed that EWS-FLI1 is repressing PEG10 expression in SKNMC cells. A previously established SKNMC cell line containing shRNA targeting EWS-FLI1 was used 51 . The shRNA expression was induced with doxycycline (100 ng/ml) and whole cell lysate for Western Blot was harvested 24, 48, and 72 h after induction (Fig. 5D). ...
... Patient data were extracted from cBioportal.org from "The Cancer Genome Atlas (TCGA), Firehose Legacy" and supplemented with "TCGA PanCancer Atlas" and "TCGA, Nature 2015" (Gatta et al. 2000s) as described before (Schnoell et al. 2021). Eleven patients were excluded due to missing or incomplete data and patients with an overall survival (OS) of less than two months due to possible postoperative complications. ...
... Utilizing the available information, an additional comparative analysis was performed between patients with biochemical recurrence and recurrence-free patients. Enrichment analysis of the significant changes between the two groups suggested differences in the TCA cycle [55,56], mitochondrial metabolism [57,58], angiogenesis [50,51], Rho GTPases [53], extracellular matrix organization [59], and ALK signaling [60], which have been associated with PCa aggressiveness and/or recurrence before. Significant differences based on the observed protein changes were also predicted in the BARD1 pathway, Interleukin-12 signaling, and a group of processes related to RNA and protein processing ( Table S4, that, to the best of our knowledge, have not yet been associated with PCa aggressiveness and may merit further investigation. ...
... A tissue microarray was constructed, and immunohistochemical staining was performed on the paraffin-embedded samples as reported previously [20]. Briefly, the samples were deparaffinized and hydrated and peroxidase activity was blocked with H 2 O 2 . ...
... In the context of these previous studies, our current findings are novel in several ways. DCLK1 is best known for its role as a tuft cell and CSC marker in gastrointestinal (GI) cancers, but a mounting body of literature supports its role in promoting non-GI malignancies including breast, lung, head and neck, and others [30,[32][33][34][35][36]. The current study represents, to our knowledge, the first reported study of DCLK1-IN-1 in a non-GI cancer. ...
... On the other hand, Bazarsad et al. [10] were able to present a significant association of the survival outcome with the expression of mutated ataxia telangiectasia and p53. Similarly, in a previous study by our group [11], a significant correlation of AF1q overexpression with an impaired survival in ACCs was shown. However, all these markers warrant a thorough immunohistological analysis. ...
... SPAG9::JAK2 induced BCL-2/MCL-1 expression via STAT1 STAT1 can regulate the expression of B-cell lymphoma 2 (BCL-2) [8,9] and myeloid cell leukemia 1 (MCL-1) [10,11], anti-apoptotic members of the BCL-2 family, which confer resistance to apoptosis and promote cell survival [12]. To elucidate the mechanism of cell survival mediated by STAT1, levels of BCL-2 and MCL-1 proteins were assessed by western blot. ...
... Respective studies provided insights into the variety of the ELMO proteins' functions as promotive factors for cell growth, proliferation and metastasis in multiple human carcinomas (Peng et al., 2016;Hu et al., 2018;Pan et al., 2019). ELMO3 is commonly suggested as a negative prognostic marker when overexpressed in different cancer types (Fan et al., 2015;Haymerle et al., 2017;Kadletz et al., 2017). Additionally, ELMO3 was recently described as a regulator of RAC1 activity promoting cell migration (Tran et al., 2021) and thereby shown to act similar to ELMO1 and ELMO2. ...